7:18 AM
 | 
May 20, 2019
 |  BC Innovations  |  Distillery Techniques

RB1 alterations predict survival in mCRPC patients treated with Zytiga or Xtandi

TECHNIQUES CATEGORY: Biomarkers

TECHNOLOGY: Gene profiling

Alterations in RB1 could help predict survival in mCRPC patients treated with Zytiga or Xtandi. In 429 patients with mCRPC, analysis of whole-exome sequencing, gene expression, histopathology, survival and time on treatment with Zytiga or Xtandi identified associations...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >